Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 5 de 5
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Front Chem ; 11: 1163486, 2023.
Article de Anglais | MEDLINE | ID: mdl-37035111

RÉSUMÉ

A short 3-step synthesis of the antiviral agent 7DMA is described herein. The nature of a major by-product formed during the key N-glycosylation of 6-chloro-7-deaza-7-iodopurine with perbenzoylated 2-methyl-ribose under Vorbrüggen conditions was also investigated. Spectroscopic analyses support that the solvent itself is converted into a nucleophilic species competing with the nucleobase and further reacting with the activated riboside in an unanticipated fashion. These findings call for a revision of reaction conditions when working with weakly reactive nucleobases in the presence of Lewis acids. 7DMA thus obtained was evaluated for its efficacy against an emerging flavivirus in vitro.

2.
Nat Commun ; 12(1): 6844, 2021 11 25.
Article de Anglais | MEDLINE | ID: mdl-34824230

RÉSUMÉ

COVID-19 manifests as a milder disease in children than adults, but the underlying mechanisms are not fully characterized. Here we assess the difference in cellular or humoral immune responses of pediatric and adult COVID-19 patients to see if these factors contribute to the severity dichotomy. Children's non-specific immune profile is dominated by naive lymphocytes and HLA-DRhighCX3CR1low dendritic cells; meanwhile, children show strong specific antibody and T cell responses for viral structural proteins, with their T cell responses differing from adults by having weaker CD8+TNF+ T cells responses to S peptide pool but stronger responses to N and M peptide pools. Finally, viral mRNA is more abundant in pediatric patients. Our data thus support a scenario in which SARS-CoV-2 infected children contribute to transmission yet are less susceptible to COVID-19 symptoms due to strong and differential responses to the virus.


Sujet(s)
Anticorps antiviraux/immunologie , COVID-19/immunologie , Immunité humorale , ARN viral , SARS-CoV-2/génétique , Vaccins synthétiques/immunologie , Adolescent , Adulte , Sujet âgé , Anticorps antiviraux/sang , Brésil , Lymphocytes T CD4+/immunologie , Lymphocytes T CD8+ , COVID-19/prévention et contrôle , Vaccins contre la COVID-19 , Enfant , Enfant d'âge préscolaire , Cytokines/sang , Femelle , Humains , Immunité innée , Mâle , Adulte d'âge moyen , ARN messager , Glycoprotéine de spicule des coronavirus/immunologie , Lymphocytes T , Protéines virales structurales/immunologie , Jeune adulte , Vaccins à ARNm
3.
Bioorg Chem ; 109: 104719, 2021 04.
Article de Anglais | MEDLINE | ID: mdl-33636437

RÉSUMÉ

Although the widespread epidemic of Zika virus (ZIKV) and its neurological complications are well-known there are still no approved drugs available to treat this arboviral disease or vaccine to prevent the infection. Flavonoids from Pterogyne nitens have already demonstrated anti-flavivirus activity, although their target is unknown. In this study, we virtually screened an in-house database of 150 natural and semi-synthetic compounds against ZIKV NS2B-NS3 protease (NS2B-NS3p) using docking-based virtual screening, as part of the OpenZika project. As a result, we prioritized three flavonoids from P. nitens, quercetin, rutin and pedalitin, for experimental evaluation. We also used machine learning models, built with Assay Central® software, for predicting the activity and toxicity of these flavonoids. Biophysical and enzymatic assays generally agreed with the in silico predictions, confirming that the flavonoids inhibited ZIKV protease. The most promising hit, pedalitin, inhibited ZIKV NS2B-NS3p with an IC50 of 5 µM. In cell-based assays, pedalitin displayed significant activity at 250 and 500 µM, with slight toxicity in Vero cells. The results presented here demonstrate the potential of pedalitin as a candidate for hit-to-lead (H2L) optimization studies towards the discovery of antiviral drug candidates to treat ZIKV infections.


Sujet(s)
Antiviraux/pharmacologie , Protéines virales non structurales/antagonistes et inhibiteurs , Protéines virales/antagonistes et inhibiteurs , Virus Zika/métabolisme , Animaux , Antiviraux/composition chimique , Survie cellulaire/effets des médicaments et des substances chimiques , Chlorocebus aethiops , Antienzymes/composition chimique , Antienzymes/pharmacologie , Flavones/pharmacologie , Apprentissage machine , Modèles moléculaires , Simulation de docking moléculaire , Conformation des protéines , Quercétine/pharmacologie , Rutoside/pharmacologie , Serine endopeptidases , Cellules Vero
5.
Cell Metab ; 32(3): 437-446.e5, 2020 09 01.
Article de Anglais | MEDLINE | ID: mdl-32697943

RÉSUMÉ

COVID-19 can result in severe lung injury. It remained to be determined why diabetic individuals with uncontrolled glucose levels are more prone to develop the severe form of COVID-19. The molecular mechanism underlying SARS-CoV-2 infection and what determines the onset of the cytokine storm found in severe COVID-19 patients are unknown. Monocytes and macrophages are the most enriched immune cell types in the lungs of COVID-19 patients and appear to have a central role in the pathogenicity of the disease. These cells adapt their metabolism upon infection and become highly glycolytic, which facilitates SARS-CoV-2 replication. The infection triggers mitochondrial ROS production, which induces stabilization of hypoxia-inducible factor-1α (HIF-1α) and consequently promotes glycolysis. HIF-1α-induced changes in monocyte metabolism by SARS-CoV-2 infection directly inhibit T cell response and reduce epithelial cell survival. Targeting HIF-1ɑ may have great therapeutic potential for the development of novel drugs to treat COVID-19.


Sujet(s)
Betacoronavirus/physiologie , Glycémie/métabolisme , Infections à coronavirus/complications , Complications du diabète/complications , Sous-unité alpha du facteur-1 induit par l'hypoxie/métabolisme , Monocytes/métabolisme , Pneumopathie virale/complications , Adulte , COVID-19 , Lignée cellulaire , Infections à coronavirus/métabolisme , Complications du diabète/métabolisme , Diabète/métabolisme , Femelle , Glycolyse , Humains , Inflammation/complications , Inflammation/métabolisme , Mâle , Adulte d'âge moyen , Monocytes/virologie , Pandémies , Pneumopathie virale/métabolisme , Espèces réactives de l'oxygène/métabolisme , SARS-CoV-2 , Transduction du signal
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...